These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

336 related items for PubMed ID: 30176673

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial.
    Agarwal R, Rossignol P, Romero A, Garza D, Mayo MR, Warren S, Ma J, White WB, Williams B.
    Lancet; 2019 Oct 26; 394(10208):1540-1550. PubMed ID: 31533906
    [Abstract] [Full Text] [Related]

  • 3. Patiromer and Spironolactone in Resistant Hypertension and Advanced CKD: Analysis of the Randomized AMBER Trial.
    Agarwal R, Rossignol P, Budden J, Mayo MR, Arthur S, Williams B, White WB.
    Kidney360; 2021 Mar 25; 2(3):425-434. PubMed ID: 35369022
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade.
    Khosla N, Kalaitzidis R, Bakris GL.
    Am J Nephrol; 2009 Mar 25; 30(5):418-24. PubMed ID: 19738369
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): results in the pre-specified subgroup with heart failure.
    Rossignol P, Williams B, Mayo MR, Warren S, Arthur S, Ackourey G, White WB, Agarwal R.
    Eur J Heart Fail; 2020 Aug 25; 22(8):1462-1471. PubMed ID: 32452085
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial.
    Bakris GL, Pitt B, Weir MR, Freeman MW, Mayo MR, Garza D, Stasiv Y, Zawadzki R, Berman L, Bushinsky DA, AMETHYST-DN Investigators.
    JAMA; 2015 Jul 14; 314(2):151-61. PubMed ID: 26172895
    [Abstract] [Full Text] [Related]

  • 14. Potassium-Binding Agents to Facilitate Renin-Angiotensin-Aldosterone System Inhibitor Therapy.
    Schaefer JA, Gales MA.
    Ann Pharmacother; 2016 Jun 14; 50(6):502-10. PubMed ID: 27009290
    [Abstract] [Full Text] [Related]

  • 15. Resistant Hypertension in Chronic Kidney Disease (CKD): Prevalence, Treatment Particularities, and Research Agenda.
    Georgianos PI, Agarwal R.
    Curr Hypertens Rep; 2020 Sep 03; 22(10):84. PubMed ID: 32880742
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Long-term effects of aldosterone blockade in resistant hypertension associated with chronic kidney disease.
    Pisoni R, Acelajado MC, Cartmill FR, Dudenbostel T, Dell'Italia LJ, Cofield SS, Oparil S, Calhoun DA.
    J Hum Hypertens; 2012 Aug 03; 26(8):502-6. PubMed ID: 21677673
    [Abstract] [Full Text] [Related]

  • 18. Evolution of Patiromer Use: a Review.
    Ali W, Bakris G.
    Curr Cardiol Rep; 2020 Jul 09; 22(9):94. PubMed ID: 32648072
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.